熱門詞: 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥
百濟(jì)神州 BeiGene
百濟(jì)神州是一家總部設(shè)在北京的中國(guó)生命科學(xué)生物科技公司,致力于探索和開發(fā)對(duì)中國(guó)和亞太地區(qū)常見癌癥有效的新型抗腫瘤藥物。
我們的研發(fā)策略將包括開發(fā)我們自己在中國(guó)實(shí)驗(yàn)室發(fā)現(xiàn)的新藥和從合作伙伴引進(jìn)的對(duì)中國(guó)和亞太地區(qū)常見癌癥有潛在療效的新藥。
為完善我們的研發(fā)能力,百濟(jì)神州正在中國(guó)創(chuàng)造一個(gè)從實(shí)驗(yàn)室到臨床試驗(yàn)的強(qiáng)大整合研發(fā)平臺(tái),用于識(shí)別癌癥患者中最有可能受益于相關(guān)藥物或治療方法的病人亞群。通過(guò)理解對(duì)藥物的敏感性和靶標(biāo)分子之間的關(guān)系, 我們將會(huì)研發(fā)出更有效和更安全的新藥。
我們正在以下領(lǐng)域建立杰出的團(tuán)隊(duì):
全新的小分子藥物和生物藥物的研發(fā)
側(cè)重于在患者中對(duì)生物標(biāo)志物識(shí)別和確認(rèn)的轉(zhuǎn)化研究
基于人類腫瘤基因分型和基因表達(dá)譜的生物信息學(xué)
2個(gè)中國(guó)臨床試驗(yàn)項(xiàng)目
以下幾個(gè)方面實(shí)力的結(jié)合帶給我們獨(dú)特的優(yōu)勢(shì):
中國(guó)和西方的研發(fā)知識(shí)和臨床實(shí)踐
大制藥公司的嚴(yán)謹(jǐn)性和穩(wěn)健性與小生物技術(shù)公司的創(chuàng)業(yè)精神
中國(guó)和西方的創(chuàng)業(yè)文化
百濟(jì)神州總部設(shè)立于中國(guó)北京。
BeiGene is a Chinese life sciences biotechnology company based in Beijing that is focused on discovering and developing innovative oncology drugs that will address unmet medical needs in cancers that are prevalent in China and the Asia-Pacific region.
Our compound portfolio will encompass novel drugs that evolve out of our discovery laboratories in China that have potential for high impact in the treatment of Chinese and Asian cancers.
To complement our discovery and development capabilities, BeiGene is creating a robust platform in China to enable the identification of specific subsets of patient populations that will identify patients who are most likely to benefit from the use of specific drugs or treatments. Understanding the link between treatment sensitivity and molecular targets will direct us to develop future drug candidates with greater efficacy and safety.
We are building core excellence in:
novel drug discovery in the areas of both small molecules and biologicals
translational research with an emphasis on biomarker identification and validation in patients
bioinformatics based on human tumor genotyping and expression profiling
2 China clinical development
Our unique organization synergistically combines the strengths of:
Chinese and Western scientific knowledge and medical practice
rigor and robustness from large pharma with biotech entrepreneurialism
Chinese and Western start-up culture
BeiGene is headquartered and operates from Beijing, China.